Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
N Engl J Med · 2025-Jun-26 · PMID 40444708
Progression-Free Survival
Figure 1.. Analysis of Progression-Free Survival by Blinded Independent Central Review. Panel A shows Kaplan-–Meier estimates of progression-free survival in the EC, EC+mFOLFOX6 and SOC arms. Panel B shows a forest plot of the analyses in pre-specified subgroups in the EC+mFOLFOX6 and SOC arms. *Analyses of EC versus SOC and EC versus EC+mFOLFOX6 are descriptive. CIs are not adjusted for multiplicity and should not be mistaken for hypothesis tests. Following a protocol amendment, enrollment into the EC arm was discontinued prematurely. † Subgroup analyses are exploratory and descriptive in nature; CIs are not adjusted for multiplicity and should not be interpreted as hypothesis tests. CI, confidence interval; EC, encorafenib and cetuximab; EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU; HR, hazard ratio; SOC, standard of care.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 3 | 2026-07-16T16:57:14+00:00 |